158 related articles for article (PubMed ID: 24961944)
21. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies.
Dukart J; Mueller K; Horstmann A; Vogt B; Frisch S; Barthel H; Becker G; Möller HE; Villringer A; Sabri O; Schroeter ML
Neuroimage; 2010 Jan; 49(2):1490-5. PubMed ID: 19770055
[TBL] [Abstract][Full Text] [Related]
22. Brain FDG PET for the Etiological Diagnosis of Clinically Uncertain Cognitive Impairment During Delirium in Remission.
Mathies F; Lange C; Mäurer A; Apostolova I; Klutmann S; Buchert R
J Alzheimers Dis; 2020; 77(4):1609-1622. PubMed ID: 32925050
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
Chételat G; Eustache F; Viader F; De La Sayette V; Pélerin A; Mézenge F; Hannequin D; Dupuy B; Baron JC; Desgranges B
Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
[TBL] [Abstract][Full Text] [Related]
24. Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early alzheimer disease in patients of a memory clinic.
Scheurich A; Muller MJ; Siessmeier T; Bartenstein P; Schmidt LG; Fellgiebel A
Dement Geriatr Cogn Disord; 2005; 20(5):271-7. PubMed ID: 16158009
[TBL] [Abstract][Full Text] [Related]
25. Non-Alzheimer types of neurodegenerative dementia: clinical and 18F-FDG-PET/CT pictures.
Grassetto G; Marzola MC; Musto A; Viniamury S; Colletti PM; Perkins AC; Rubello D
Nucl Med Commun; 2014 Nov; 35(11):1085-92. PubMed ID: 25162962
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease.
Gjerum L; Andersen BB; Bruun M; Simonsen AH; Henriksen OM; Law I; Hasselbalch SG; Frederiksen KS
PLoS One; 2021; 16(3):e0248413. PubMed ID: 33711065
[TBL] [Abstract][Full Text] [Related]
27. Frontal network syndrome testing: clinical tests and positron emission tomography brain imaging help distinguish the 3 most common dementia subtypes.
Hoffmann M
Am J Alzheimers Dis Other Demen; 2013 Aug; 28(5):477-84. PubMed ID: 23677732
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of therapeutic response to donepezil by positron emission tomography.
Shimada A; Hashimoto H; Kawabe J; Higashiyama S; Kai T; Kataoka K; Tagawa R; Kawarada Y; Nakanishi A; Inoue K; Shiomi S; Kiriike N
Osaka City Med J; 2011 Jun; 57(1):11-9. PubMed ID: 22106763
[TBL] [Abstract][Full Text] [Related]
29. FDG PET imaging in patients with pathologically verified dementia.
Hoffman JM; Welsh-Bohmer KA; Hanson M; Crain B; Hulette C; Earl N; Coleman RE
J Nucl Med; 2000 Nov; 41(11):1920-8. PubMed ID: 11079505
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature.
Bohnen NI; Djang DS; Herholz K; Anzai Y; Minoshima S
J Nucl Med; 2012 Jan; 53(1):59-71. PubMed ID: 22173840
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of
Perini G; Rodriguez-Vieitez E; Kadir A; Sala A; Savitcheva I; Nordberg A
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):612-622. PubMed ID: 32734458
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET for the diagnosis of fever of unknown origin: a Japanese multi-center study.
Kubota K; Nakamoto Y; Tamaki N; Kanegae K; Fukuda H; Kaneda T; Kitajima K; Tateishi U; Morooka M; Ito K; Minamimoto R; Murakami K
Ann Nucl Med; 2011 Jun; 25(5):355-64. PubMed ID: 21344168
[TBL] [Abstract][Full Text] [Related]
33. Voxel-based classification of FDG PET in dementia using inter-scanner normalization.
Thiele F; Young S; Buchert R; Wenzel F
Neuroimage; 2013 Aug; 77():62-9. PubMed ID: 23541799
[TBL] [Abstract][Full Text] [Related]
34. Brain PET in suspected dementia: patterns of altered FDG metabolism.
Brown RK; Bohnen NI; Wong KK; Minoshima S; Frey KA
Radiographics; 2014; 34(3):684-701. PubMed ID: 24819789
[TBL] [Abstract][Full Text] [Related]
35. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia.
Garibotto V; Montandon ML; Viaud CT; Allaoua M; Assal F; Burkhard PR; Ratib O; Zaidi H
Clin Nucl Med; 2013 Mar; 38(3):e112-7. PubMed ID: 23357822
[TBL] [Abstract][Full Text] [Related]
36. B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: impact on voxel-based statistical single-subject analysis.
Wenzel F; Young S; Wilke F; Apostolova I; Arlt S; Jahn H; Thiele F; Buchert R
Neuroimage; 2010 Apr; 50(3):994-1003. PubMed ID: 20053378
[TBL] [Abstract][Full Text] [Related]
37. Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders.
Minoshima S; Mosci K; Cross D; Thientunyakit T
Semin Nucl Med; 2021 May; 51(3):230-240. PubMed ID: 33546814
[TBL] [Abstract][Full Text] [Related]
38. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
39. MR-based attenuation correction using ultrashort-echo-time pulse sequences in dementia patients.
Cabello J; Lukas M; Förster S; Pyka T; Nekolla SG; Ziegler SI
J Nucl Med; 2015 Mar; 56(3):423-9. PubMed ID: 25678486
[TBL] [Abstract][Full Text] [Related]
40. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study.
Laforce R; Buteau JP; Paquet N; Verret L; Houde M; Bouchard RW
Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):324-32. PubMed ID: 20539026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
